Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-09-27 am EDT
3748.00 JPY   +0.21%
09/20Puma Biotech in Exclusive License Deal With Takeda
DJ
09/20Takeda Pharmaceutical Says Health Canada Authorized Treatment for Post-Transplant Cytomegalovirus Infection
MT
09/20Health Canada approves Takeda's LIVTENCITY™ (maribavir) the First and Only Treatment for Adults with Post-Transplant Cytomegalovirus (CMV) infection
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Posts Higher Fiscal Q1 Core Profit, Revenue

07/28/2022 | 03:29am EDT


© MT Newswires 2022
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
09/20Puma Biotech in Exclusive License Deal With Takeda
DJ
09/20Takeda Pharmaceutical Says Health Canada Authorized Treatment for Post-Transplant Cytom..
MT
09/20Health Canada approves Takeda's LIVTENCITY™ (maribavir) the First and Only Treatm..
AQ
09/19Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewa..
BU
09/16Takeda Pharmaceutical Says It Received Positive Opinion for Post-Transplant Cytomegalov..
MT
09/16Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Po..
BU
09/16Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Po..
CI
09/16Takeda's Drug to Battle Post-Transplant Virus Recommended for Marketing Approval by EU
DJ
09/14Takeda Selects New Partners for Global Corporate Social Responsibility Program to Stren..
AQ
09/14Prometheus Laboratories Announces Partnership with Takeda Pharmaceutical to Launch CDPA..
CI
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2023 3 779 B 26 096 M 26 096 M
Net income 2023 311 B 2 147 M 2 147 M
Net Debt 2023 2 953 B 20 392 M 20 392 M
P/E ratio 2023 18,7x
Yield 2023 4,80%
Capitalization 5 816 B 40 155 M 40 155 M
EV / Sales 2023 2,32x
EV / Sales 2024 2,26x
Nbr of Employees 47 347
Free-Float 96,4%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 748,00 JPY
Average target price 4 581,33 JPY
Spread / Average Target 22,2%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Masami Iijima Chairman
Andrew S. Plump Director, President-Research & Development
Michael E. Mendelsohn Chief Medical & Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED19.22%40 202
JOHNSON & JOHNSON-3.14%435 655
ELI LILLY AND COMPANY12.76%292 179
ROCHE HOLDING AG-19.31%253 262
ABBVIE INC.4.29%249 673
PFIZER, INC.-25.35%245 989